ClinicalTrials.gg
Active, not recruitingNCT05653804i-tech PPCUpdated Feb 12, 2026

Impact of Tele-visit on Patients Continous Positive Airway Pressure (CPAP) Follow-up by Home Care Provider

An interventional study of tele-visit in Obstructive Sleep Apnea, sponsored by AGIR à Dom. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by AGIR à Dom · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 201 studies in Sleep Apnea, Obstructive with a site in France — 39 open to participants now, 48 under way, 4 of them phase 3. Sleep Apnea, Obstructive · France.

Enrollment
13th of 133
320 · median 52
Started
2023
with 7 others
No phase
105 of 201
18 open now
Primary completion
2026-05
later than 13 of 47 live
Registered
160th of 201
by date
Lead sponsor
4 of 201
AGIR à Dom

Among the 201 studies in Sleep Apnea, Obstructive with a site in France, this one is the 13th largest by enrollment of the 133 interventional ones that give a count, is one of 8 that started in 2023, is one of 105 with no phase, reaches primary completion later than 13 of the 47 other live ones, and was the 160th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

39 of the 201 studies in Sleep Apnea, Obstructive with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 201 studies in Sleep Apnea, Obstructive with a site in France, or all of them as a file.
02

Study summary

To determine the impact of telecare on continous positive airway pressure (CPAP) patients follow up by home care provider (HCP)

Read the detailed description

Obstructive sleep apnea (OSA) syndrome is a chronic respiratory pathology affecting 4% of french adult population and reference treatment for moderate to severe forms of obstructive sleep apnea syndrome (OSA) is continuous positive airway pressure (CPAP).

However, CPAP treatment is binding, so nearly a quarter of patients abandoning treatment at 1 year and nearly half of them at 3 years. Support for these patients on CPAP must therefore be optimal and seek patient satisfaction; HCP (Home Care Provider) plays an important role in this follow-up.

Since 2018 in France, teleconsultation entered on common law but was little used. The pandemic has disrupted the habits of care and patients monitoring by developing remote monitoring. Home Care Providers (HCP) have also been forced to organize remote monitoring, particularly for the annual follow-up visit (technical tele-visit).

The impact of the annual follow-up visits of HCP by tele-visit has never been clinically evaluated. If its clinical relevance were demonstrated and patient satisfaction confirmed, this follow-up modality could become, like telecare, a new standard for the follow-up of patients on CPAP.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • tele-visit
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • CPAP ≥ 12 months and annual followed by "AGIR à dom" health care provider.
  • Compliance with CPAP ≥ 4h/night and AHI ≤ 5 events/hour on machine report for the 3 months prior to inclusion

Exclusion criteria

Exclusion Criteria:

  • Follow-up by AGIR à dom. for an other service than package F9.1 : CPAP follow-up and remote monitoring
  • Unacceptable level of mask leakage
  • Patient unavailable or willing to move within the next 12 months to an area not covered by AGIR à dom.
  • Patient considered by the investigator to be unfit for a tele-visit
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    tele-visit by HCP

    Patients receive a annual CPAP remote visit by HCP technician, then home visit the following year

    Procedure: tele-visit

  • No intervention
    home visit by HCP

    Standard care : patients receive an annual CPAP home visit by HCP technician

Interventions

  • Proceduretele-visit

    The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.

06

What researchers measure

Primary outcomes

  1. To compare CPAP compliance between the two management modalities

    CPAP mean compliance between intervention and control groups, adjusted for the three months prior to inclusion : in hours/day, collected on the CPAP remote monitoring report

    Time frame: Over the 3 months (tele)visit follow-up

Secondary outcomes

  1. To compare overall patient satisfaction between the two management modalities

    The Consumer Satisfaction Questionnaire (CSQ-8) mean score between intervention and control groups, after the CPAP (tele-)visit follow-up . The overall score is calculated by adding the respondent's evaluation score (item evaluation) for each item on the scale. For the CSQ-8 version, the scores therefore range from 8 to 32, with higher values indicating greater satisfaction.

    Time frame: Immediately after the (tele-)visit follow-up

  2. To compare the impact on daytime sleepiness between the two management modalities

    Epworth Sleepiness Scale (ESS) mean score between intervention and control group. All items are assumed to be integers (0-3). The ESS score is the sum of 8 item scores. 0-10 = normal range of sleepiness in healthy adults 11 to 14 = mild sleepiness 15 to 17 = moderate sleepiness 18 to 24 = severe sleepiness

    Time frame: At 3 months after (tele-)visit follow-up

  3. To compare impact on quality of life between the two management modalities

    The EuroQol 5 Dimensions - 5 levels (EQ5D-5L) questionnaire mean score between intervention and control group, adjusted on the baseline score. it's composed of two parts : A visual analog scale (20 cm line, graduated from 0 to 100 where patient indicates his or her current state of health, 0 being the worst and 100 the best) the completion of 5 items evaluating mobility, autonomy, daily activities, pain or discomfort and anxiety or depression. 1. indicating no problem 2. indicating slight problems 3. indicating moderate problems 4. indicating severe problems 5. indicating unable to/extreme problems Each state is referred to by a 5-digit code.

    Time frame: At 3 months after (tele-)visit follow-up

  4. To compare CPAP compliance in medium term between the two management modalities

    CPAP mean compliance between intervention and control group : in hours/day, collected on the CPAP remote monitoring report

    Time frame: Over the 12 months (tele)visit follow-up

  5. To compare impact on CPAP continuation between the two management modalities

    Rate of CPAP removal between intervention and control group ; the number of CPAP unbundling among participants

    Time frame: Over the 12 months (tele)visit follow-up

  6. To compare treatment effectiveness between the two management modalities

    Apnea Hypopnea Index (AHI) mean between intervention and control group. AHI corresponds to the number of apneas and hypopneas per hour of sleep, collected on the CPAP remote monitoring report.

    Time frame: Over the 12 months (tele)visit follow-up

  7. To compare treatment quality on mask leakage between the two management modalities

    Leakage mean level between intervention and control group

    Time frame: Over the 3 months (tele)visit follow-up

  8. To compare occurrence frequency of CPAP-related adverse effect(s) between the two management modalities

    The Side-Effects to CPAP treatment Inventory (SECI) mean score between the intervention and control group. Each of the 15 items relating to side effects associated with CPAP treatment has three subscales: frequency, breadth of the side effect, and impact on CPAP use. For each subscale, the patient will complete a five-point Likert-type scale, so the possible range for each subscale is 15 to 75. A higher score indicates greater frequency of side effects, greater breadth of side effects, and greater intensity of side effects.

    Time frame: Over the 3 months (tele)visit follow-up

  9. To compare follow-up impact in addition to the annual visit between the two management modalities

    Mean number of calls and visits made per patient between control and intervention group

    Time frame: Over the 12 months (tele)visit follow-up

  10. To evaluate failed visits number between the two care modalities

    Mean number of (tele-)visits requiring a reprogramming (absence, technical problem, last minute deprogramming, home visit...)

    Time frame: Over the 12 months (tele)visit follow-up

  11. To evaluate patient satisfaction with tele-visits

    The Televisit Satisfaction Questionnaire (TSQ) mean score 14 items, rated between 1 and 5 by the patient. The sum of the items corresponds to a score ranging from 14 to 70.

    Time frame: Immediately after the (tele-)visit follow-up

  12. To evaluate technician satisfaction with tele-visits

    The Televisit Satisfaction Questionnaire (TSQ) questionnaire mean score 14 items, rated between 1 and 5 by the patient. The sum of the items corresponds to a score ranging from 14 to 70.

    Time frame: Immediately after the (tele-)visit follow-up

  13. Comparison of the environmental impact associated with the two patient follow-up methods (home visit versus tele-visit)

    Comparison of the carbon emissions generated by each care modality, calculated over the entire patient participation period and expressed in kgCO₂e, considering only the impact of the follow-up method itself, without including the individual use of the CPAP device.

    Time frame: Over the 12 months (tele)visit follow-up

Other outcomes

  1. To evaluate patient overall satisfaction regarding clinical study participation

    Survey Satisfaction

    Time frame: Over the 3 months (tele)visit follow-up

07

Study locations

1 site
  • AGIR à dom.
    Meylan, 38240, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for May 2026, 37 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 37 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2022
First posted
Dec 16, 2022
StartActual
Apr 1, 2023
Primary completionEst.
May 11, 2026
CompletionEst.
May 11, 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05653804
Lead sponsor
AGIR à Dom
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Apr 1, 2023
Primary completion
May 11, 2026 (estimated)
Completion
May 11, 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Jean Christian BOREL, PhD
principal investigator · AGIR à Dom

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion